Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC5508 in Advanced Solid Tumors
NCT07620041Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of MHB088C in solid tumor (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Correlation between plasma concentration of QLC5508 payload and change from baseline in QTc interval at Month 6, Maximum Plasma Concentration of QLC5508 at Month 6 and 3 more. Started Jun 2026; status: recruiting.
02
Drugs
MHB088C
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07620041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07620041.